Celgene reaches settlement with Actavis

31-01-2018

Celgene reaches settlement with Actavis

miodrag ignjatovic / iStockphoto.com

Biopharmaceutical company Celgene has reached an agreement with Actavis that will terminate pending patent litigation over Abraxane (paclitaxel protein-bound particles for injectable suspension).


Celgene, Actavis, cancer treatment, biopharmaceuticals, patent litigation, generics, inter partes review

LSIPR